Rhumbline Advisers Sells 537 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Rhumbline Advisers decreased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 0.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,524 shares of the company’s stock after selling 537 shares during the period. Rhumbline Advisers owned approximately 0.27% of TransMedics Group worth $6,023,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in TMDX. Vanguard Group Inc. grew its position in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after purchasing an additional 40,860 shares in the last quarter. FIL Ltd grew its position in TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock valued at $62,372,000 after purchasing an additional 218,961 shares in the last quarter. Braidwell LP bought a new position in TransMedics Group in the fourth quarter valued at $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock valued at $56,307,000 after purchasing an additional 128,474 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after purchasing an additional 349,403 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of the business’s stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director now directly owns 12,134 shares of the company’s stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider now directly owns 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is owned by insiders.

TransMedics Group Price Performance

TMDX stock opened at $143.04 on Friday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm has a market cap of $4.84 billion, a P/E ratio of 152.17 and a beta of 2.10. The company’s 50-day moving average price is $107.25 and its two-hundred day moving average price is $82.02.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period last year, the firm earned $0.35 EPS. The business’s quarterly revenue was up 48.2% compared to the same quarter last year. On average, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer increased their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.11.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.